TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate. The TCRX stock yearly return is shown above.
The yearly return on the TCRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|